Hospital-acquired pneumonia: Microbiological data and potential adequacy of antimicrobial regimens

European Respiratory Journal

Volumn 20, Issue 2, 2002, Pages 432-439

  Leroy, O ^a   Giradie, P ^a   Yazdanpanah, Y ^a   Georges, H ^a   Alfandari, S ^a   Sanders, V ^a   Devos, P ^a   Beaucaire, G ^a  

^a CENTRE HOSPITALIER   (France)

Author keywords

Antibiotics; Intensive care; Nosocomial pneumonia; Pneumonia; Resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CORYNEBACTERIUM; DRUG EFFICACY; ENTEROBACTER; ESCHERICHIA COLI; FREQUENCY ANALYSIS; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; NON PROFIT ORGANIZATION; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; VALIDATION PROCESS; AGED; CROSS INFECTION; DRUG EFFECT; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK FACTOR; TIME;

AGED; ANTIBIOTICS; CROSS INFECTION; FEMALE; GRAM-NEGATIVE BACTERIA; HUMAN; MALE; MIDDLE AGE; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; ANTI-BACTERIAL AGENTS; HUMANS; MIDDLE AGED;

EID: 0035989827     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00267602     Document Type: Article

References (22)

1. Pneumonia in intubated trauma patients
2. Risk factors for nosocomial pneumonia: Comparing adult critical-care population
3. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay
4. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient
5. The effect of late-onset ventilator-associated pneumonia in determining patient mortality
6. Effect of hospital-acquired ventilator-associated pneumonia on mortality of severe community-acquired pneumonia
7. Effect of ventilator-associated pneumonia on mortality and mortality
8. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies
9. Bacteriemic nosocomial pneumonia. Analysis of 172 episodes from a single metropolitan area
10. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
11. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
12. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria
13. Society of healthcare epidemiology of America and infectious diseases society of America joint committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
14. A new simplified acute physiologic score (SAPS II) based on European/North American multicenter study
15. The value of routine microbial investigation in ventilator-associated pneumonia
16. Antibiotic resistance in the Intensive Care Unit
17. Prevention and control of vancomycin resistance in Gram-positive coccal microorganisms: Fire prevention and fire fighting
18. Hospital-acquired pneumonia and de-escalation of antimicrobial treatment
19. Emergence of vancomycin resistance in Staphylococcus aureus
20. Variations in etiology of ventilator-associated pneumonia across four treatment sites Implications for antimicrobial prescribing practices
21. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia